|
Abbott Enrolls First U.S. Patient in Global EXCEL Trial
|
06 October 2011 |
|
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
|
24 August 2011 |
|
Many Americans May Have Low Vitamin D Levels
|
09 August 2011 |
|
Abbott Confirms Long-Term Commitment to HIV Care
|
19 July 2011 |
|
Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
|
22 June 2011 |
|
Abbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
|
10 June 2011 |
|
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
|
11 May 2011 |
|
Abbott Reports 17.4 Percent Sales Growth
|
21 April 2011 |
|
Abbott Supports Relief Efforts in Japan
|
14 March 2011 |
|
Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter
|
26 January 2011 |
|
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
|
10 January 2011 |
|
EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
|
20 December 2010 |
|
Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
|
24 November 2010 |
|
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
|
22 November 2010 |
|
Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year
|
08 November 2010 |
|
Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine
|
08 October 2010 |
|
Abbott's XIENCE V(R) Shows Continued Strong Performance
|
24 September 2010 |
|
Abbott Honored for Workplace Leadership for the Tenth Consecutive Year
|
15 September 2010 |
|
Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years
|
14 September 2010 |
|
Abbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
|
08 September 2010 |